October 1, 2020 By Huy Tran, MD, and Thao Ha, MD Myopia is the most common refractive error worldwide and is estimated...
June 24, 2020 By Dwight Akerman, OD, MBA, FAAO, FBCLA Chief Medical Editor, Review of Myopia Management The use of atropine to...
June 12, 2020 The clinical-stage ophthalmic biopharmaceutical company Eyenovia is developing a microdose treatment that is designed to improve the delivery of...
May 1, 2020 By Laura Kirkeby, CO The use of atropine has been known to slow the progression of myopia for many...
April 1, 2020 By Dwight Akerman, OD, MBA, FAAO Chief Medical Editor, Review of Myopia Management Topical low-dose atropine is an...
There are two strategies to consider for stopping atropine treatment.
March 1, 2020 By Dwight Akerman, OD, MBA, FAAO Chief Medical Editor, Review of Myopia Management To assess the effects of interventions...
Individual interventions may not result in the expected efficacy.
This summary of an International Myopia Institute (IMI) white paper was created by and is used with permission from the Centre for...
Presently, only atropine, pirenzepine, and 7-methylxanthine are shown to reduce myopia progression in human trials.
The researchers concluded that topical low-dose atropine appears to be safe and effective in a cohort of European schoolchildren.
A summary of the LAMP Study results
Axial elongation rate is faster in younger children undergoing ortho-k treatment.
When should one start atropine treatment for myopes?